Global CDMO Growth Jubilant Pharmova operates a broad CDMO platform including Sterile Injectables, Ophthalmic formulations, and API manufacturing, with multiple facilities serving regulated markets such as the USA and Europe. This presents an opportunity to upsell and cross-sell additional contract manufacturing capacity, including sterile fill-finish lines and API supply, to existing oncology, auto-immune, and specialty drug clients.

Radiopharma & Immunotherapy Expansion The company has a radiopharma network of 45 radiopharmacies in the US and an Allergy Immunotherapy footprint across US, Canada, Europe and Australia. This signals potential to cross-sell radiopharma services and immunotherapy manufacturing capabilities to biotech firms and hospitals looking to expand radiopharmaceutical products and allergy-related therapies.

Strategic Partnerships Recent collaboration with Pierre Fabre to expand biologics and antibody-drug conjugate capabilities in Europe indicates a strategy to scale advanced therapeutics. Target biotech and pharma players pursuing biologics, ADCs and European manufacturing footprints for late-stage programs or regional supply chains.

Financial Momentum FY26 revenue growth and notable quarterly sales increases, coupled with FDA facility approvals for line expansions, point to strengthening production capacity and capability. This creates selling points for reliability-focused clients seeking scalable supply agreements and long-term capacity commitments.

Talent & Capacity Ready A sizable global workforce and expanded Spokane facility with line 3 approval demonstrate readiness to accommodate additional CDMO work. This supports outreach to new customers seeking robust, compliant manufacturing partners with diverse capabilities including sterile fill-finish, ophthalmics, and drug discovery support.